Modification of PGO activity by specific uptake inhibitors fluoxetine, nisoxetine and LR5182.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000494:pharmacology; D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D002415:Cats; D003655:Decerebrate State; D004123:Dimethylamines / Q000494:pharmacology; D004569:Electroencephalography; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D005473:Fluoxetine / Q000494:pharmacology* / Q000031:analogs & derivatives; D005829:Geniculate Bodies / Q000187:drug effects*; D008297:Male; D009778:Occipital Lobe / Q000187:drug effects*; D010647:Phenyl Ethers / Q000494:pharmacology*; D011149:Pons / Q000187:drug effects*; D011437:Propylamines / Q000494:pharmacology*; D012110:Reserpine / Q000494:pharmacology; D013997:Time Factors
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D004123:Dimethylamines; D010647:Phenyl Ethers; D011437:Propylamines; D005473:Fluoxetine; C011386:nisoxetine; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D012110:Reserpine; D010134:Fenclonine